Potomac Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
Other funds holding XBI
Potomac Capital Management's XBI Position: Q1 2026 in Review
Potomac Capital Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2026, closing a stake of 8,000 shares — an estimated $975K sold.
Potomac Capital Management first reported a position in XBI in Q2 2022 and held it in 8 quarters. The position peaked at $1.03M in Q4 2023. 813 funds tracked by Wall St. Rank hold XBI as of Q1 2026.
- Potomac Capital Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2026 after selling out during the quarter.
- Potomac Capital Management sold 8,000 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $975K.
- Potomac Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q2 2022 and held it in 8 quarters.
- Potomac Capital Management's State Street SPDR S&P Biotech ETF position peaked at $1.03M in Q4 2023.
- 813 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.
Based on Potomac Capital Management's 13F filing for Q1 2026, filed 14 May 2026.